GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
about
Sex differences in the physiology of eatingAn amylin analog used as a challenge test for Alzheimer's disease.Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasationAmylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons.Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes.Biomarkers of Alzheimer's disease among Mexican Americans.Antipsychotic-like actions of the satiety peptide, amylin, in ventral striatal regions marked by overlapping calcitonin receptor and RAMP-1 gene expression.mTOR and regulation of energy homeostasis in humans.Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?GLP-1 and Amylin in the Treatment of Obesity.Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model.Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier.Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells.Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.Polymorphisms in the Glucagon-Like Peptide 1 Receptor () Gene Are Associated with the Risk of Coronary Artery Disease in Chinese Han Patients with Type 2 Diabetes Mellitus: A Case-Control Study
P2860
Q27007513-FA31FCD3-ED6C-438F-8F1E-26F97075BE05Q33655621-62D5EC4E-F4D5-40AD-8A32-4CB6F874855FQ35027845-CF1F2992-06AB-4A70-91F2-B3EB48E4F0A6Q35690970-0A631E58-1455-422D-9090-B91CC604E07AQ35693015-1ACEEDBB-580A-4C08-8A2A-DA70E5A96587Q35889726-C447D354-D479-4AC5-9AA8-CC6DE3D09943Q36153252-52A60215-69EA-492F-A4DE-A7AA68E783D7Q36716970-FA74E154-338B-4021-AC84-3514488DC727Q37650208-3B8DE94C-B6F5-4309-B4B0-8D4F69796077Q38113695-A49922AC-911E-46F0-984B-8471863678BDQ38239648-76B1062E-AD06-441C-8257-07506391F7A6Q38677851-7B5DE410-A86A-4CA5-BE34-CF4D4CBE23DEQ38942152-F938BE50-51EA-42C7-BFDC-D0BC01B94253Q39136356-3B43682A-09E4-483A-BAAF-5E2E5DF5F0D7Q43238779-DE0AF71A-41B6-4A03-B084-C42B507BA41BQ47095823-3B5AB351-BB8C-4658-BF75-16B7403C5804Q47277568-0B892488-249F-4440-8340-61BCD11B2BCAQ48130202-E4211AE5-9F2D-464D-951C-AB520567E703Q57115794-525ABFDA-5646-4AB4-8286-48C32D528DEC
P2860
GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@ast
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@en
type
label
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@ast
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@en
prefLabel
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@ast
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@en
P2093
P2860
P1476
GLP-1R and amylin agonism in m ...... nisms and future opportunities
@en
P2093
David G Parkes
Jonathan D Roth
Mary R Erickson
Steve Chen
P2860
P304
P356
10.1111/J.1476-5381.2011.01537.X
P407
P577
2012-05-01T00:00:00Z